GENERATE BIOMEDICINES INC · held by 1 fund · data as of 2026-06-03
Sector
Healthcare
Industry
Biotechnology
Market cap
$1.53B
Price
$12.74
12-mo
+0.80%
Held by
1 fund
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a ther…